A Diffusion-Based and Dynamic 3D-Printed Device That Enables Parallel in Vitro Pharmacokinetic Profiling of Molecules.

The process of bringing a drug to market involves many steps, including the preclinical stage, where various properties of the drug candidate molecule are determined. These properties, which include drug absorption, distribution, metabolism, and excretion, are often displayed in a pharmacokinetic (PK) profile. While PK profiles are determined in animal models, in vitro systems that model in vivo processes are available, although each possesses shortcomings. Here, we present a 3D-printed, diffusion-based, and dynamic in vitro PK device. The device contains six flow channels, each with integrated porous membrane-based insert wells. The pores of these membranes enable drugs to freely diffuse back and forth between the flow channels and the inserts, thus enabling both loading and clearance portions of a standard PK curve to be generated. The device is designed to work with 96-well plate technology and consumes single-digit milliliter volumes to generate multiple PK profiles, simultaneously. Generation of PK profiles by use of the device was initially performed with fluorescein as a test molecule. Effects of such parameters as flow rate, loading time, volume in the insert well, and initial concentration of the test molecule were investigated. A prediction model was generated from this data, enabling the user to predict the concentration of the test molecule at any point along the PK profile within a coefficient of variation of ∼ 5%. Depletion of the analyte from the well was characterized and was determined to follow first-order rate kinetics, indicated by statistically equivalent (p > 0.05) depletion half-lives that were independent of the starting concentration. A PK curve for an approved antibiotic, levofloxacin, was generated to show utility beyond the fluorescein test molecule.

[1]  Stephen C Jacobson,et al.  Diffusion coefficient measurements in microfluidic devices. , 2002, Talanta.

[2]  K. Bowker,et al.  Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models. , 2002, International journal of antimicrobial agents.

[3]  J. DiMasi,et al.  The cost of biopharmaceutical R&D: is biotech different? , 2007 .

[4]  L. Engstrand,et al.  New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms , 1996, Antimicrobial agents and chemotherapy.

[5]  Jerome J. Schentag.  Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. , 1999, Journal of chemotherapy.

[6]  Van V. Brantner,et al.  Estimating the cost of new drug development: is it really 802 million dollars? , 2006, Health affairs.

[7]  J. Blaser,et al.  Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model , 1985, Antimicrobial Agents and Chemotherapy.

[8]  C. Kloft,et al.  In vitro pharmacodynamic models to determine the effect of antibacterial drugs. , 2010, The Journal of antimicrobial chemotherapy.

[9]  J. Rotschafer,et al.  An in Vitro Pharmacodynamic Model to Simulate Antibiotic Behavior of Acute Otitis Media with Effusion , 1992, Pharmaceutical Research.

[10]  K. Birkness,et al.  A tissue culture bilayer model to study the passage of Neisseria meningitidis , 1995, Infection and immunity.

[11]  Bethany C Gross,et al.  3D printed microfluidic devices with integrated versatile and reusable electrodes. , 2014, Lab on a chip.

[12]  M HolmanChristopher,et al.  The Biotechnology Industry Organization (BIO) and Pharmaceutical Research and Manufacturers of America (PhRMA) Seek En Banc Review of Ariosa Diagnostics v. Sequenom , 2015 .

[13]  J. Blaser,et al.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance , 1987, Antimicrobial Agents and Chemotherapy.

[14]  Ali Khademhosseini,et al.  Microfluidics for drug discovery and development: from target selection to product lifecycle management. , 2008, Drug discovery today.

[15]  T. Bergan,et al.  An in vitro model for monitoring bacterial responses to antibiotic agents under simulated in vivo conditions , 2005, Infection.

[16]  M. Nishida,et al.  Laboratory evaluation of FR10612, a new oral cephalosporin derivative. , 1976, The Journal of antibiotics.

[17]  D. Fish,et al.  The Clinical Pharmacokinetics of Levofloxacin , 1997, Clinical pharmacokinetics.

[18]  P. Welling,et al.  An in vitro model for the study of antibacterial dosage regimen design. , 1982, Journal of pharmaceutical sciences.

[19]  P. Stewart,et al.  Comparison of recalcitrance to ciprofloxacin and levofloxacin exhibited by Pseudomonas aeruginosa bofilms displaying rapid-transport characteristics , 1997, Antimicrobial agents and chemotherapy.

[20]  G L Drusano,et al.  Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. , 1998, JAMA.

[21]  Jerome J. Schentag,et al.  Achieving an Optimal Outcome in the Treatment of Infections , 1999, Clinical pharmacokinetics.

[22]  M. Dickson,et al.  Key factors in the rising cost of new drug discovery and development , 2004, Nature Reviews Drug Discovery.

[23]  E. White,et al.  Comparison of in vitro models for the study of Mycobacterium tuberculosis invasion and intracellular replication , 1996, Infection and immunity.

[24]  A. Manz,et al.  Revisiting lab-on-a-chip technology for drug discovery , 2012, Nature Reviews Drug Discovery.

[25]  E. H. White,et al.  An In Vitro Tissue Culture Bilayer Model To Examine Early Events in Mycobacterium tuberculosisInfection , 1999, Infection and Immunity.

[26]  S. Lockwood,et al.  A 3D printed fluidic device that enables integrated features. , 2013, Analytical chemistry.

[27]  S. Chung,et al.  [Bactericidal activity of antibiotics as a function of pharmacokinetic constants. I. Experimental dynamic model simulating variations in the concentrations of antibiotics]. , 1982, Pathologie-biologie.

[28]  H. Derendorf,et al.  Pharmacokinetic-Pharmacodynamic Modeling of the Antibiotic Effect of Piperacillin in Vitro , 2004, Pharmaceutical Research.

[29]  Bethany C Gross,et al.  Evaluation of 3D printing and its potential impact on biotechnology and the chemical sciences. , 2014, Analytical chemistry.

[30]  I. Haller.  Combined action of decreasing concentrations of azlocillin and sisomicin on pseudomonas aeruginosa as assessed in a dynamic in vitro model , 2005, Infection.

[31]  V. Tamassia,et al.  New In Vitro Model to Study the Effect of Antibiotic Concentration and Rate of Elimination on Antibacterial Activity , 1978, Antimicrobial Agents and Chemotherapy.

[32]  R. Davis,et al.  Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. , 1994, Drugs.

[33]  Chengpeng Chen,et al.  3D-printed fluidic devices enable quantitative evaluation of blood components in modified storage solutions for use in transfusion medicine. , 2014, The Analyst.

[34]  A. Widmer,et al.  In vivo verification of in vitro model of antibiotic treatment of device-related infection , 1995, Antimicrobial agents and chemotherapy.

[35]  J. Guggenbichler,et al.  Kill kinetics and regrowth pattern of bacteria exposed to antibiotic concentrations simulating those observed in vivo. , 1985, The Journal of antimicrobial chemotherapy.

[36]  K I Kaitin,et al.  Deconstructing the Drug Development Process: The New Face of Innovation , 2010, Clinical pharmacology and therapeutics.

[37]  G. Whitesides,et al.  Rapid Prototyping of Microfluidic Systems in Poly(dimethylsiloxane). , 1998, Analytical chemistry.

[38]  O. Cars,et al.  Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model , 1996, Antimicrobial agents and chemotherapy.

[39]  Clifton E. Barry,et al.  Tuberculosis — metabolism and respiration in the absence of growth , 2005, Nature Reviews Microbiology.

[40]  Hartmut Derendorf,et al.  Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Kill Curves versus MIC , 2004, Antimicrobial Agents and Chemotherapy.

[41]  M. Takano,et al.  Pharmacokinetic-pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model. , 2008, Journal of pharmaceutical sciences.

[42]  B. Nies.  Comparative activity of cefixime and cefaclor in an in vitro model simulating human pharmacokinetics , 1989, European Journal of Clinical Microbiology and Infectious Diseases.

[43]  B. Meibohm,et al.  In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB. , 2010, Future medicinal chemistry.

[44]  S. Falkow,et al.  Model for invasion of human tissue culture cells by Neisseria gonorrhoeae , 1988, Infection and immunity.

[45]  Roger L. White.  What In Vitro Models of Infection Can and Cannot Do , 2001, Pharmacotherapy.

[46]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.